> ## Content Index > Fetch the complete content index at: https://entrepreneurplus.co.uk/llms.txt > Use this file to discover other available public pages before exploring further. # UK Female Founders Built a Boom With One Winner - URL: https://entrepreneurplus.co.uk/uk-female-founders-built-a-boom-with-one-winner/ - Published: 2026-09-10T10:00:52.000Z - Updated: 2026-09-10T10:00:51.000Z - Description: UK Female Founders have built a booming FemTech sector, but the funding story remains starkly uneven. With 106 companies and just one unicorn, the real question is whether capital will finally catch up with the women building the market. - Author: Sharoni Banerjee - Tags: Sector Spotlights --- 106 UK FemTech companies exist today, when a decade ago, there were only 11. That’s an 864% increase that makes it, by Beauhurst's count, the fastest-growing sector it tracks, and that growth has been built almost entirely by UK female founders, in a category that exists specifically because mainstream healthcare investment overlooked them. Put that history next to the fact that only one of these companies has ever reached a billion-dollar valuation, and the growth story starts to look less like a market maturing and more like a market that has learned how to start companies led by UK female founders without yet learning how to fund them past the first stage. This gap is the actual story of UK female founders in FemTech going into 2026, not whether the category is exciting, because everyone in venture will tell you it is, but why a decade of proven consumer demand, real revenue and a genuinely fast-growing company count still produces a funding pattern this lopsided for the women building it. --- ## A sector shaped like a pyramid with almost no top UK FemTech companies have raised £477.6 million all-time, with 87% of that - £417.5 million - arriving since 2020, annual investment peaked at £177.1 million in 2024, before falling 56% to £77.2 million in 2025, still the second-best year on record. On paper, that's a sector accelerating. Now if we look at the stage breakdown, the picture changes, out of all the top 50 UK FemTech companies by funding, 23 sit at Seed stage and 20 at Venture stage, only four have reached the Growth stage, two are Established, and the dataset records a single exit. > "Over the last decade, the UK femtech ecosystem has expanded, both in terms of deal activity and funding levels... Whilst companies in femtech have relied heavily on angel investors and angel networks to fund their growth ambitions, dynamics are shifting, with more venture capital and PE investors appearing in funding rounds. However, this is just the beginning and there is still more to do." — **Vicky Protano, Corporate Partner, Mills & Reeve.** --- ## Flo Health is the exception holding up the whole story The period-tracking app became the UK's first FemTech unicorn in 2024 on a $200 million round from General Atlantic, and has since raised £206.5 million total - 43% of the entire top 50's combined funding, more than the next nine companies put together. It is the single data point holding up the sector's "FemTech works" narrative. Next to it, SheMed's £37.5 million is the largest Seed-stage raise anywhere in the Beauhurst top 50 - a striking amount of capital for a company still formally classified at the earliest funding stage, and a clear illustration of just how much money the market is willing to commit before a FemTech company is allowed to be called "de-risked." The distance between Flo Health and everyone else isn't a long tail, it’s a cliff, and it's UK female founders at Seed and Venture stage who are stuck beneath it. --- ## The gender health gap nobody put in the funding thesis The instinct is to file this under the same story as every other female founder's funding gap with not enough women on investment committees, not enough familiarity with women's health among male-majority partners. That's real, and well documented elsewhere, but it's not the whole mechanism, and the parts that get missed are more specific and more fixable than "bias." A February 2026 report from CensHERship and The Case For Her found that every women's-health company surveyed had run into barriers accessing basic financial infrastructure, these include payment processors and ad platforms that still misclassify FemTech products under adult-content or medical-device codes never updated for the sector. One UK FemTech founder in the Beauhurst top 50 has reportedly been blocked from using the word "vagina" in a product listing on a platform that permits the word "semen." That is certainly not investor sentiment, that's plumbing, and it sits underneath the wider gender health gap as much as any funding statistic does. Layered on top of that is a payer problem that has nothing to do with product quality. DLA Piper's investors and founders describe fragmented reimbursement pathways as the recurring point where clinically compelling FemTech products stall. WEF and BCG put a number on the scale of the gender health gap: women's health captures roughly 6% of private healthcare investment globally, against a population split of roughly half. Our related coverage has looked at this from the founder's side -[***Why Valerie's FemTech Funding Story Matters***](https://entrepreneurplus.co.uk/inside-femtech-investment-uk-the-founders-betting-everything-on-valeries-next-chapter/) traces what happens when a company with genuine retail traction still can't close the capital to scale past that exact stage. --- ## What the Women's Health Strategy actually commits to Government policy has started catching up to the scale of the problem, at least on paper. The renewed Women's Health Strategy, published in April 2026, launched the NIHR R&D Innovation Catalyst and a £1.5 million FemTech challenge fund. £1.5 million in public grant funding, against a sector that raised £177 million in its best private year, tells you plainly how much of this problem the Women's Health Strategy has decided is the government's job to fix versus how much it's leaving to private capital - capital that isn't reliably reaching UK female founders past Seed. --- ## Where the market actually says yes If there's a lane where the structural conservatism is genuinely easing, it's employer-side menopause and menstrual benefits, not consumer health apps. Peppy's position as the UK's second-best-funded FemTech company isn't an anomaly. Peppy launched menopause support as an employee benefit in 2018 - a world first - and has since raised through to a $45 million Series B, backed by AlbionVC, Felix Capital and Seedcamp among others, working with over 250 enterprise clients including Accenture, Adobe and Disney. > "We already dominate Europe's employer-funded gender-based healthcare market... Over the last few years we've seen employers wake up to the vital importance of personalized care. They know that it's a non-negotiable factor in attracting, engaging and retaining the best colleagues, particularly women." — **Dr Mridula Pore, Co-Founder and Co-CEO, Peppy** That's the market signalling where it's willing to underwrite risk: not "will individual women pay for this app," but "will an HR budget pay for this benefit." That lane is about to get a regulatory tailwind, which is the UK's gender pay gap and menopause action plan guidance, launched in March 2026, which becomes compulsory for large employers from April 2027\. The menopause action plan mandate is the clearest near-term catalyst in this entire piece: a fixed date after which demand stops being optional. ![](https://storage.ghost.io/c/05/a4/05a4a052-18ab-4836-8924-ec8b322c371c/content/images/2026/09/Menopause-action-plan.png.png) NHS Women’s Health Clinic ## What we're watching The honest read on UK female founders building in FemTech going into 2026 is that they've solved the easier problem, which is persuading the market that this is worth building, and have not yet solved the harder one, and that is what happens at the stage past proof of concept. Whether that changes because of the menopause action plan mandate, because growth-stage investors decide the Beauhurst numbers finally look de-risked enough, or because the Women's Health Strategy's early interventions have time to compound,we don't know yet. What's crystal clear is that *"UK FemTech is growing"* and that *"UK female founders are still structurally stuck at Seed"* are both true at once. --- **Sources:* Beauhurst; DLA Piper; CensHERship and The Case For Her ("The Bias Burden," February 2026); World Economic Forum / BCG; GOV.UK, Women's Health Strategy (April 2026); Mills & Reeve; AlbionVC / Peppy funding announcements.*